Investigation of the Therapeutic Value of Verbascum pyramidatum Bieb. for Obesity

Year 2023, Volume: 51 Issue: 3, 251 - 258, 16.07.2023

Sıla Sener , Merve Badem , Mehmet Çatalbaş , Şeyda Kanbolat , Ufuk Özgen , Nevin Ulaş Çolak

https://doi.org/10.15671/hjbc.1196913

Abstract

Nowadays, one of the therapeutic approaches for obesity is the use pancreatic lipase inhibitors which reduce the digestion and absorption of fats. Most research indicates that natural sources which have a lipase inhibitory effect, may be utilized to treat obesity. Verbascum pyramidatum is one of the potential natural sources for obesity, and it has been demonstrated to have anti-inflammatory, antidiabetic, and regulatory effects on lipid metabolism. With this study, V. pyramidatum's potential lipase inhibitor effect, it is aimed to reveal its value in the treatment of obesity.
In vitro spectroscopic method was used to determine the lipase inhibitory effect of V. pyramidatum. The quantitative investigation of V. pyramidatum's phenolic metabolites with antiobesity activity was carried out utilizing the Reverse Phase-High Performance Liquid Chromatography method.
In this reported study, it was proven that extract and all fractions had an impact that inhibited lipase, with the ethyl acetate extract showing the highest inhibitory effect. Additionally, it was revealed through HPLC analysis that the species included p-OH benzoic acid, coumaric acid, quercetin, sinapic acid, and syringaldehyde. It has been demonstrated that V. pyramidatum may be a promising candidate for obesity treatment, but further investigations are required to use it as a therapeutic agent.

Keywords

Lipase, Obesity, RP-HPLC, Verbascum pyramidatum

Supporting Institution

TÜBİTAK

Project Number

1919B012102417

Thanks

We would like to acknowledge the Turkish Scientific and Technical Research Council (TUBITAK) for funding of the study.

References

• (1) B.Z. Altunkaynak ve E. Özbek, Obezite: nedenleri ve tedavi seçenekleri, Van Tıp Derg., 13 (2006) 138-142.
• (2) Y. Zhang, B. Huang, W. Yang, S. Zhong, S. Lai, He J. Zhao, S. Cai, S. Lv, C. Wang, and Y. Jia, Correlations between endocrine hormones and cognitive function in patients with obesity: a cross-sectional study, Obes. Surg., 32 (2022) 2299-2308.
• (3) J.G. Kang, and C.Y. Park, Anti-obesity drugs: a review about the ireffects and safety, Diabetes Metab. J., 36 (2012) 13-25.
• (4) X. Qi, Review of the clinical effect of orlistat, IOP Conf. Ser.: Mater. Sci. Eng., 301 (2018)1-8.
• (5) S. Patra, S. Nithya, B. Srinithya, and S.M. Meenakshi, Review of medicinal plants for anti-obesity activity, Transl. Biomed., 6 (2015)3-21.
• (6) J.W. Yun, Possible anti-obesity therapeutics from nature-A review, Phytochemistry, 71 (2010) 1625-1641.
• (7) C. Rodríguez-Pérez, A. Segura-Carretero, and M. del Mar Contreras, Phenolic compounds as natural and multifunctional anti-obesity agents: A review, Crit. Rev. Food Sci. Nutr., 59 (2019) 1212-1229.
• (8) G.C. Yen, H.L. Cheng, L.Y. Lin, S.C. Chen, and C.L. Hsu, The potential role of phenolic compounds on modulating gut microbiota in obesity, J Food Drug Anal, 28 (2020) 1211-1228.
• (9) S. Alan, A.B. Gökman, Investigation of morphological, morphometric and anatomical characteristics of endemic Verbascum orgyale Boiss. & Heldr. Biological Diversity and Conservation, 8 (2015) 94-103.
• (10) F. Jamshidi-Kia, Z. Lorigooini, S. Asgari, and K. Saeidi, Iranian species of Verbascum: a review of botany, phytochemistry, and pharmacological effects, Toxin Rev., 38 (2019) 255-262.
• (11) S. Küçük, Endemik Verbascum bellum Hub. and Mor.(Scrophulariaceae) türünün anatomik özellikleri, Anadolu Üniversitesi Bilim ve Teknoloji Dergisi-C Yaşam Bilimleri ve Biyoteknoloji, 6 (2017) 22-30.
• (12) İ. Tatlı, and Z.Ş. Akdemir, Traditional uses and biological activities of Verbascum species, Fabad J. Pharm. Sci., 31 (2006) 85-96.
• (13) Y. Bustanji, I.M., M. Al-Masri Mohammad, M. Hudaib, K. Tawaha, and H. Tarazi, Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba, J Enzyme Inhib Med Chem, 26 (2011) 453-459.
• (14) S.O. Sener, U. Ozgen, S. Kanbolat, N. Korkmaz, M. Badem, H. Hanci, E. Yenilmez, R. Aliyazıcıoğlu, and G.S. Iscan, Investigation of therapeutic potential of three endemic Cirsium species for global health problem obesity, S. Afr. J. Bot., 141 (2021) 243-254.
• (15) N. Korkmaz, S.O. Şener, Ş. Kanbolat, M. Badem, R. Aliyazicioğlu, M. Abudayyak, and Ozgen, U, Investigation of antioxidant, cytotoxic, tyrosinase inhibitory activities, and phenolic profiles of Green, White, and Black Teas, Turkish J. Biochem., 44 (2019) 278-288.
• (16) N. Aktar, N.K. Qureshi, and H.S. Ferdous, Obesity: A review of pathogenesis and management strategies in adult, Delta Med. Coll. J., 5 (2017) 35-48.
• (17) A. Hruby, and F.B., The epidemiology of obesity: A big picture, Pharmacoeconomics, 33 (2015) 673-689.
• (18) S. Feng, L. Reuss, and Y. Wang, Potential of natural products in the inhibition of adipogenesis through regulation of PPARγ expression and/or its transcriptional activity, Molecules, 21 (2016) 1278-1297.
• (19) B. Kaila, and M. Raman, Obesity: A review of pathogenesis and management strategies, Can. J. Gastroenterol. Hepatol., 22 (2008) 61-68.
• (20) G.S. Kim, H.J. Park, J.H. Woo, M.K. Kim, P.O. Koh, W. Min, Y.G. Ko, C.H. Kim, C.K. Won, and J.H. Cho, Citrus aurantium flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells, BMC Complement Altern. Med., 12 (2012) 1-10.
• (21) A. Yiğit, and V. Yiğit, Economic burden of obesity-related comorbidities in Turkey, Gümüşhane Univ. Sağlık Bilim. Derg., 8 (2019) 223-230.
• (22) B.D.S. Bonamichi, E. Bezerra Parente, R.B. Dos Santos, R. Beltzhoover, J. Lee, and J.E. Nunes Salles, The challenge of obesity treatment: A review of approved drugs and new therapeutic targets, J. Obes. Eat. Disord., 4 (2018) 1-10.
• (23) S. Jayarathne, I. Koboziev, O.H. Park, W. Oldewage-Theron, C.L. Shen, D. Moustaid Jhade, M.P. Padmaa, and G. Usha, Isolation of phytoconstituents from the leaves of Chenopodium album Linn, J. Pharm. Res., 2 (2009) 1192-1193.
• (24) N. Al Shukor, R. Ravallec, J. Van Camp, K. Raes, and G. Smagghe, Flavonoids stimulate cholecystokinin peptide secretion from the enteroendocrine STC-1 cells, Fitoterapia, 113 (2016) 128-131.
• (25) C.L. Hsu, and G.C. Yen, Phenolic compounds: evidence for inhibitory effects against obesity and their underlying molecular signaling mechanisms, Mol. Nutr. Food Res., 52 (2008) 53-61.
• (26) W.C. Chang, J.S.B. Wu, C.W. Chen, P.L. Kuo, H.M. Chien, Y.T. Wang, and S.C. Shen, Protective effect of vanillic acid against hyperinsulinemia, hyperglycemia and hyperlipidemia via alleviating hepatic insulin resistance and inflammation in high-fat diet (HFD)-fed rats, Nutrients, 7 (2015) 9946-9959.
• (27) M.A. Alam, N. Subhan, H. Hossain, M. Hossain, H.M. Reza, M.M. Rahman, and M.O. Ullah, Hydroxycinnamic acid derivatives: a potential class of natural compounds for the management of lipid metabolism and obesity, Nutr. Metab., 13(2016) 1-13.
• (28) S.C. Kuo, H.H. Chung, C.H. Huang, and J.T. Cheng, Decrease of hyperglycemia by syringaldehyde in diabetic rats, Horm. Metab., Res., 46 (2014) 8-13.
• (29) M. Gayathri, and K. Kannabiran, Antidiabetic activity of 2-hydroxy 4-methoxy benzoic acid isolated from the roots of Hemidesmus indicus on streptozotocin-induced diabetic rats, Int J Diabetes & Metabolism, 17 (2019) 53-57.
• (30) L. Aguirre, N. Arias, M. Teresa Macarulla, A. Gracia, and M. Portillo, Beneficial effects of quercetin on obesity and diabetes, Open Nutraceuticals J., 4 (2011) 189-198.
• (31) E. Karalija, A. Parić, S. Dahija, R. Bešta-Gajević, and S. Ćavar Zeljković, Phenolic compounds and bioactive properties of Verbascum glabratum subsp. bosnense (K. Malý) Murb., an endemic plant species, Nat. Prod. Res., 34 (2020) 2407-2411.
• (32) A. Dalar, Y. Guo, and I. Konczak, Phenolic composition and potential anti-inflammatory properties of Verbascum cheiranthifolium var. cheiranthifolium leaf, J. Herb. Med., 4 (2014):195-200.